Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals (ATNM) today and set a price target of $3. The company’s shares opened today at $0.58.
McCarthy said:
“Actinium announced the initiation of the Phase 1/2 combination trial of CD-33 antibody Actimab-A with venetoclax (Venclexta) in relapsed/refractory acute myeloid leukemia (r/r AML). This is the second of three combination trials with Actimab to initiate (CLAG-M combo underway, Venetoclax + HMA triple next).”
According to TipRanks.com, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -2.8% and a 33.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Sonoma Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
Actinium Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $4.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $0.87 and a one-year low of $0.33. Currently, Actinium Pharmaceuticals has an average volume of 745.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Actinium Pharmaceuticals, Inc. engages in the development of targeted therapies for patients with cancers lacking effective treatment options. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells.
